Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corporation

J&J MedTech provides medical devices and solutions for various healthcare needs, self-described as part of Johnson & Johnson.

J&J MedTech

Neopharm provides analytical services for the life sciences industry. Their services include GMP quality control testing and R&D solutions to accelerate product development.

Neopharm

Bio-Techne is a global developer, manufacturer, and supplier of high-quality reagents, analytical instruments, and precision diagnostics.

Metric
Company Name	Bio-Techne Corporation	J&J MedTech	Neopharm
Symbol	TECH
MSH ID	COM:BIO-TECHNE	COM:JNJMEDICALDEVICES	COM:NEOPHARMLABS
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Medical Devices	Pharmaceuticals
Country	US	US	CA
Stage
Employee Count	3.20K
Website	bio-techne.com	jnjmedicaldevices.com	neopharmlabs.com
LinkedIn
Founders

Metric
Market Cap	11.36B
Enterprise Value
Monthly Web Traffic		258.88K
Web Traffic Growth		-0.06
Valuation
Raised Capital

Metric
Revenue	1.16B
Revenue (LTM)
Revenue (NTM)
Gross Profit	848.04M
EBITDA	318.40M
Operating Income	206.69M
Net Income	168.10M
EPS	1.07
Diluted EPS	1.05
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.68
Operating Profit Margin	0.23
EBITDA Margin	0.27
Net Profit Margin	0.20
Return on Equity	0.11
Return on Assets	0.08
Return on Capital Employed	0.10

COM:BIO-TECHNE

Bio-Techne

Last Close

71.05

22/11 21:00

Market Cap

11.36B

Beta: -

Volume Today

620.62K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	42.63
P/B Ratio	5.12
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.44
EV Multiple	35.74

Metric
Days Sales Outstanding	66.19
Days Payables Outstanding
Days Inventory Outstanding	180.03
Operating Cycle	253.67
Cash Conversion Cycle	215.75
Asset Turnover	0.43

Metric
Operating Cash Flow	298.98M
Free Cash Flow	236.10M
Cash Flow to Debt	0.90
Operating Cash Flow/Sales	0.27
Free Cash Flow Yield	0.02

Metric
Cash & Equivalents	151.79M
Accounts Receivable
Inventory	179.73M
Goodwill
Debt to Capitalization	0.22
Debt to Assets	0.20
Current Ratio	4.37
Quick Ratio	2.88

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03
R&D to Revenue	0.08
SG&A to Revenue